Treatment progress of intrahepatic cholangiocarcinoma

doi:10.3760/cma.j.issn.1673,422X.2016.01.017

Abstract

Abstract: Surgical resection is still the mainstay for treatment of intrahepatic cholangiocarcinoma (ICC). Gemcitabine and cisplatin is a systemic therapy practice standard for patients with nonresectable ICC. Neoadjuvant therapy with liver transplantation may be a new therapeutic option for patients with ICC. In addition, radiotherapy, hepatic intraarterial therapy, ablation therapy and molecular targeted therapy are important components of comprehensive therapy for ICC.

Key words: Bile ducts, intrahepatic, Bile duct neoplasms, Therapeutics

Luo Mengchao, Ding Chaofeng, Wu Jian, Zheng Shusen. Treatment progress of intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(1): 60-63.

References

［1］ Charbel H, AlKawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis［J］. CurrGastroenterol Rep, 2011, 13(2): 182-187. DOI:10.1007/s1189401101788. ［2］ Lubezky N, Facciuto M, Harimoto N, et al. Surgical treatment of intrahepatic cholangiocarcinoma in the USA［J］. J Hepatobiliary Pancreat Sci, 2015, 22(2): 124-130. DOI:10.1002/jhbp.157. ［3］ Bergeat D, Sulpice L, Rayar M, et al. Extended liver resections for intrahepatic cholangiocarcinoma: friend or foe?［J］. Surgery, 2015, 157(4): 656-665. DOI:10.1016/j.surg.2014.11.011. ［4］ De Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multiinstitutional analysis of prognostic factors and lymph node assessment［J］. J Clin Oncol, 2011, 29(23): 3140-3145. DOI:10.1200/JCO.2011.35.6519. ［5］ Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma［J］. J Hepatol, 2014, 60(6): 1268-1289. DOI:10.1016/j.jhep.2014.01.021. ［6］ Sapisochin G, Rodríguez De Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?［J］. Am J Transplant, 2014, 14(3): 660-667. DOI:10.1111/ajt.12591. ［7］ Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24year experience in a single center［J］. Arch Surg, 2011, 146(6): 683-689. DOI:10.1001/archsurg.2011.116. ［8］ Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma［J］. Curr Opin Gastroenterol, 2012, 28(3): 258265. DOI:10.1097/MOG.0b013e32835168db. ［9］ Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours:amulticentrerandomised phase Ⅱ study—the UK ABC01 study［J］. Br J Cancer, 2009, 101(4): 621-627. DOI: 10.1038/sj.bjc.6605211. ［10］ Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］. N Engl J Med, 2010, 362(14): 1273-1281. DOI:10.1056/NEJMoa0908721. ［11］ Fisher SB, Patel SH, Kooby DA, et al. Lymphovascular and perineuralinvasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multiinstitution analysis［J］. HPB (Oxford), 2012, 14(8): 514-522. DOI:10.1111/j.14772574.2012.00489.x. ［12］ Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma［J］. Radiat Oncol, 2012, 7: 67. DOI:10.1186/1748-717X-7-67. ［13］ Jiang W, Zeng ZC, Tang ZY, et al. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases［J］. J Cancer Res Clin Oncol, 2010, 136(9): 13231331. DOI:10.1007/s00432-010-0783-1. ［14］ Giorgio A, Calisti G, De Stefano G, et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centreexperience［J］. Anticancer Res, 2011, 31(12): 4575-4580. ［15］ Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection［J］. Eur J Radiol, 2011, 80(3): e221-e225. DOI:10.1016/j.ejrad.2010.09.019. ［16］ Vogl TJ, Naguib NN, NourEldin NE, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success［J］. Int J Cancer, 2012, 131(3): 733-740. DOI:10.1002/ijc.26407. ［17］ Shen WF, Zhong W, Liu Q, et al. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study［J］. World J Surg, 2011, 35(9): 20832091. DOI:10.1007/s00268-011-1171-y. ［18］ Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting beadtransarterial chemoembolization and systemic chemotherapy［J］. Eur J Gastroenterol Hepatol, 2012, 24(4): 437443. DOI:10.1097/MEG.0b013e3283502241. ［19］ AlAdra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium90 radioembolization: a systematic review and pooled analysis［J］. Eur J Surg Oncol, 2015, 41(1): 120127. DOI:10.1016/j.ejso.2014.09.007. ［20］ Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study［J］. Lancet Oncol, 2010, 11(12): 1142-1148. DOI:10.1016/S1470-2045(10)70247-3. ［21］ Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, openlabel, randomised, phase 3 study［J］. Lancet Oncol, 2012, 13(2): 181-188. DOI:10.1016/S1470-2045(11)70301-1.

[1]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[2]	Wang Jun, Jia Xiuhong. TGF-β/Smad signal pathway and acute leukemia [J]. Journal of International Oncology, 2023, 50(8): 498-502.
[3]	Huang Rui, Zhang Yunqing. Clinical efficacy of anlotinib monotherapy in second-line treatment of extensive stage small cell lung cancer with poor PS score [J]. Journal of International Oncology, 2023, 50(12): 705-710.
[4]	Xu Hangcheng, Wu Yun, Wang Jiayu. Research progress of breast cancer with low HER2 expression [J]. Journal of International Oncology, 2022, 49(9): 513-516.
[5]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[6]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[7]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.
[8]	Zhou Xinyu, Jia Xiuhong. Research progress of ferroptosis in the treatment of leukemia [J]. Journal of International Oncology, 2022, 49(12): 759-762.
[9]	Zhou Weiwen, Sun Xiaonan. Research progress of radiotherapy in extrahepatic cholangiocarcinoma [J]. Journal of International Oncology, 2020, 47(7): 431-435.
[10]	Zhang Dandan, Yue Hongyun, Zhang Baihong. Adaptive therapy of human cancers: targeting cancer evolution [J]. Journal of International Oncology, 2020, 47(6): 368-371.
[11]	Zhang Baihong, Yue Hongyun. Application of selective CDK4/6 inhibitors in solid cancers therapy [J]. Journal of International Oncology, 2019, 46(6): 350-357.
[12]	Zhang Yu, Xu Bin, Wang Dongmei. Curative effect analysis of 3DCRT combined with thalidomide and GEMOX regimen in advanced intrahepatic cholangiocarcinoma [J]. Journal of International Oncology, 2019, 46(5): 262-266.
[13]	Xue Dong, Xia Xiuliang, Song Dekun, Xiang Tinghai, Wang Jianqiang, Gong Bengang. Expression and clinical significance of cullin 4A in cholangiocarcinoma [J]. Journal of International Oncology, 2019, 46(3): 153-156.
[14]	Mo Qiuping, Chen Yiding, Wang Xiaochen, . Application of CDK4/6 inhibitors in the treatment of hormone receptorpositive breast cancer [J]. Journal of International Oncology, 2019, 46(10): 617-619.
[15]	Ni Chuandou, Song Chunfeng, Yang Mingjun, Xing Peng, Zhang Wei. Progress in the study of preoperative evaluation and surgical treatment of hilar cholangiocarcinoma [J]. Journal of International Oncology, 2018, 45(11): 692-695.